Topical Roflumilast for Plaque Psoriasis

Skin Therapy Lett. 2023 Sep;28(5):1-4.ABSTRACTRoflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.PMID:37734074
Source: Skin Therapy Letter - Category: Dermatology Authors: Source Type: research